阿茲海默氏症治療藥之全球市場 是由出版商Koncept Analytics在2009年03月所出版的。
這份英文市場調查報告書包含25 pages 價格從美金700起跳。
Abstract
The Alzheimer' s disease (AD) diagnosis and therapy market is expanding with
increasing number of cases worldwide. The current scenario shows bright
outlook for diagnosis market. As early diagnosis of AD is not possible, there
is a strong need of an early detection technique. United States, Europe and
Japan are the three major markets for the treatment of AD. In China, the
diagnosis and drug treatment of Alzheimer' s disease is extremely low, which
represents a potential opportunity for market players.
The worldwide Alzheimer disease market is led by sales of Eisai/Pfizer and
Aricept. Eisai/Pfizer' s Aricept (donepezil) and Forest pharmaceutical' s
Namenda (memantine) are the market leaders in the United States. After
cardiovascular diseases and cancer, AD is the third largest market in the
world in terms of cost of treatment of the disease.
Aging population is a major cause of increasing number of Alzheimer patients
and driving AD diagnosis and treatment market. Urbanization also contributes
to the growing AD market. The unmet clinical needs are driving competitors to
focus on R&D which ultimately leads to new product introduction and helps in
market growth.
The present report analyzes Alzheimer' s disease treatment and diagnosis market
and discusses major drugs being used for the treatment of AD in United States,
Japan and China. It analyses major growth drivers and opportunities present in
the market. The report also discusses competition prevailing in the industry
and an overview of the leading companies and their business strategies. The
section on market forecast helps market players to develop business strategies
accordingly.
Table of Contents
1. Introduction
- 1.1 Types of Prescription Medications
- 1.2 Industry Facts
2. Alzheimer Drugs Market
- 2.1 Worldwide Alzheimer Drug Market
- 2.1.1 Global Market Value
- 2.1.2 Growth Rate
- 2.1.3 Market Value by Drugs
- 2.1.4 Market Share
- 2.2 Alzheimer' s Market: United States
- 2.2.1 Market Value
- 2.2.2 Market Share
- 2.3 China Alzheimer Market
3. Market Features
- 3.1 Key Trends
- 3.1.1 Dementia Prevailing in Aging People
- 3.1.2 Urbanization and Gender Differences
- 3.1.3 East-West differences
- 3.2 Market Opportunities
- 3.2.1 Unmet Clinical Needs
- 3.2.2 Opportunity in Diagnosis Market
- 3.2.3 Increasing Cases in Europe
- 3.3 Significant Developments
- 3.3.1 RFID Chip Implants
- 3.3.2 Herbal supplement improves memory
- 3.3.3 Blood Test to Detect Alzheimer' s disease
4. Competitive Landscape
- 4.1 Drug Competition
- 4.2 Leading Players
5. Company Profiles
- 5.1 Forest Laboratories
- 5.1.1 Overview
- 5.1.2 Business Strategies
- 5.1.3 Comprehensive Set of Products
- 5.1.4 Limited Geographical Presence/Narrow Customer Base
- 5.2 Neuro-Hitech
- 5.2.1 Overview
- 5.2.2 Business Strategies
- 5.2.3 Commercialization of Primary Product
- 5.2.4 Licensing Agreements
- 5.2.5 Product Line Extensions
- 5.3 Elan Corporation
- 5.3.1 Overview
- 5.3.2 Business Strategies
- 5.3.3 Focus on Developing Innovative Products
- 5.3.4 Distribution Pattern
6. Market Outlook
- 6.1 US Market
- 6.2 European Market
List of Tables
- Global Alzheimer Market Value by Drugs (2007)
- US Alzheimer Market by Drug Sales (2001-06)
- US Alzheimer Market - Total Dispensed Scripts (2001-06)
- Clinical Trials Phases of Alzheimer Drugs
- US Alzheimer Treatment Market Forecast (2010-15E)
- European Alzheimer Market Forecast (2011-15E)
- Forest Laboratories- Sales by Business Segments (2006-08)
- Forest Laboratories- Drug Sales (2006-08)
- Elan Corp. - Revenue by Business Segments (2005-07)
List of Charts
- Types of Prescription Medications
- Global Alzheimer Market Value (2006-07)
- Global Drugs Market Share (2007)
- Drugs Market Value & Growth Rate (2006)
- Global Alzheimer Drugs Market (2005)
- Alzheimer' s Top Brands - Market Share (2001-06)
- Medicine Market Share in China (2007)
- Rate of Occurrence of Alzheimer in Western Countries (2007)
- Alzheimer Drugs - Competitive Landscape
- Alzheimer RX Trends
- Neuro-Hitech - Revenue & Net Income (2005-07)
